STOCK TITAN
  1. Home
  2. News
  3. PHVS

Pharvaris N.V. Ordinary Shares - PHVS STOCK NEWS

Welcome to our dedicated page for Pharvaris N.V. Ordinary Shares news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris N.V. Ordinary Shares stock.

Pharvaris N.V. (PHVS) is a pioneering, clinical-stage biopharmaceutical company dedicated to developing novel, oral bradykinin B2 receptor antagonists for the treatment and prevention of hereditary angioedema (HAE) and other related conditions. With a strategic focus on unmet medical needs in rare diseases, Pharvaris aims to provide safer, more effective, and easier-to-administer alternatives to currently available injectable therapies.

Core Business and Expertise

Pharvaris is spearheaded by a team with profound expertise in HAE, including the discovery and approval of the HAE treatment icatibant. The company leverages this foundation to develop small, potent molecules targeting the bradykinin B2 receptor—a clinically validated therapeutic target. By inhibiting bradykinin signaling at this receptor, Pharvaris' lead candidate, deucrictibant, offers potential for both acute and prophylactic treatment of HAE and other bradykinin-mediated diseases.

Current Projects and Achievements

  • Pharvaris has made significant progress in its clinical development programs. Notably, the U.S. FDA has lifted the clinical hold on deucrictibant, allowing the continuation of global development, including Phase 2 and Phase 3 trials.
  • The company's Phase 2 CHAPTER-1 study demonstrated positive top-line data for deucrictibant in preventing HAE attacks, with significant reductions in attack rates at both 20 mg/day and 40 mg/day doses.
  • Deucrictibant is being developed in two formulations: a rapid-onset capsule for acute treatment and an extended-release tablet for long-term prophylaxis.

Future Outlook

Pharvaris is preparing for the global Phase 3 CHAPTER-3 study and continues to engage with regulatory authorities to align on study designs. The company is also expanding its research into other bradykinin-mediated conditions, aiming to broaden its therapeutic portfolio.

Financial Condition and Market Presence

Strong financial performance and strategic investor support underscore Pharvaris’ potential. The company’s financial health allows it to fund ongoing and future clinical trials while building infrastructure for the anticipated launch of deucrictibant. Pharvaris is committed to operating transparently, with regular updates provided to its stakeholders through its website and regulatory filings.

With a clear mission to transform the treatment landscape for rare diseases, Pharvaris stands out for its innovative approach and dedication to improving patient outcomes.

News

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

Rhea-AI Summary
Pharvaris (PHVS) to participate in Leerink Global Biopharma Conference 2024 to discuss oral bradykinin B2 receptor antagonists for hereditary angioedema treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
-
News

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

Rhea-AI Summary
Pharvaris (PHVS) announces significant reduction in HAE attack rate with deucrictibant treatment. The CHAPTER-1 Phase 2 trial shows an 84.5% reduction in monthly attack rate with deucrictibant compared to placebo. The treatment is well-tolerated with mild adverse events. The results support the development of deucrictibant as a potential option to treat and prevent HAE attacks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
clinical trial
-
News

Pharvaris Announces Extraordinary Meeting of Shareholders

Rhea-AI Summary
Pharvaris (PHVS) schedules an extraordinary general meeting of shareholders on March 6, 2024, to discuss key developments in their clinical-stage oral bradykinin B2 receptor antagonist for hereditary angioedema treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
News

Pharvaris to Present at the WSAAI Annual Meeting 2024

Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) has announced the acceptance of two abstracts for poster presentation at the Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024. The abstracts will focus on the efficacy and safety of their oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema attacks. The presentation will be held at the Grand Hyatt Kauai Resort & Spa in Koloa, Hawaii, on February 4-8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
conferences
-
News

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Rhea-AI Summary
Pharvaris (PHVS) announced that the FDA has lifted the clinical hold on the Investigational New Drug application for deucrictibant for the prophylactic treatment of hereditary angioedema attacks. This enables the company to progress the global development of deucrictibant for long-term prophylaxis and to resume the open-label portion of their Phase 2 proof-of-concept study in the U.S. The company also plans to request an End-of-Phase 2 meeting with the FDA to align on key elements of the anticipated global Phase 3 study of deucrictibant extended-release tablets for the prophylactic treatment of HAE attacks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.27%
Tags
none
-
News

Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities

Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) provided business updates and outlined its strategic priorities for 2024. The company demonstrated deucrictibant’s potential for the prevention and treatment of HAE attacks. They are operating from a strong financial position and anticipate an important execution year with the initiation of RAPIDe-3 and the submission of nonclinical study results to the FDA. They are also preparing to initiate the global pivotal study, CHAPTER-3, for the prophylaxis against HAE attacks. The company closed a $300 million underwritten offering, extending their cash runway for at least two years. Jochen Knolle, Ph.D., co-founder of Pharvaris, is transitioning to strategic advisor to the CEO and Executive Committee.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
News

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) presented positive results from the RAPIDe-1 Phase 2 trial of deucrictibant capsules for the on-demand treatment of hereditary angioedema (HAE) attacks at the Global Allergy and Asthma Excellence Network (GA²LEN) UCARE Conference. The results showed rapid reduction in time to symptom relief and resolution of attacks, reduced use of rescue medication, and well-tolerated capsules at all dose levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
clinical trial
-
News

Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants

Rhea-AI Summary
Pharvaris N.V. (PHVS) announced the pricing of an underwritten offering of 11,125,000 ordinary shares at $24.00 per share, and pre-funded warrants to purchase 1,375,000 ordinary shares at $23.99 per pre-funded warrant, expected to generate approximately $300 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.14%
Tags
offering
-
News

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) announced positive top-line data from the CHAPTER-1 Phase 2 clinical study, with deucrictibant demonstrating statistically significant results as an oral preventative treatment for hereditary angioedema (HAE). The primary endpoint was met, showing an 84.5% reduction in monthly attack rate compared to placebo. Deucrictibant was well-tolerated, and secondary endpoints also demonstrated clinically meaningful improvement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.14%
Tags
clinical trial
News

Pharvaris to Present at the GA²LEN UCARE Conference 2023

Rhea-AI Summary
Pharvaris (Nasdaq: PHVS) announced the acceptance of one abstract for oral presentation and two abstracts for poster presentation at the GA²LEN UCARE Conference 2023. The company is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Presentation details include the RAPIDe-1 Phase2 Trial Results, Symptom Relief Definitions in HAE, and Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant. Pharvaris is a bronze level sponsor of the conference, and the presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.58%
Tags
conferences

FAQ

What is the current stock price of Pharvaris N.V. Ordinary Shares (PHVS)?

The current stock price of Pharvaris N.V. Ordinary Shares (PHVS) is $18.54 as of January 8, 2025.

What is the market cap of Pharvaris N.V. Ordinary Shares (PHVS)?

The market cap of Pharvaris N.V. Ordinary Shares (PHVS) is approximately 1.0B.

What is Pharvaris N.V. focused on?

Pharvaris N.V. is focused on developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) and other bradykinin-mediated diseases.

What is deucrictibant?

Deucrictibant is a potent, selective, and orally available antagonist of the bradykinin B2 receptor developed by Pharvaris for the treatment and prevention of HAE attacks.

What recent achievements has Pharvaris made?

Pharvaris has announced positive top-line data from the Phase 2 CHAPTER-1 study and received FDA approval to lift the clinical hold on deucrictibant, allowing the continuation of global development.

What clinical trials are ongoing at Pharvaris?

Pharvaris is conducting Phase 2 and Phase 3 clinical trials, including the CHAPTER-1 and CHAPTER-3 studies, to evaluate the efficacy and safety of deucrictibant in treating and preventing HAE attacks.

What makes deucrictibant unique?

Deucrictibant offers the potential for both rapid-onset and extended-release formulations, providing patients with effective oral alternatives to injectable therapies for HAE.

How is Pharvaris positioned financially?

Pharvaris is financially strong, with investor support enabling the advancement of its clinical programs and preparation for the commercial launch of deucrictibant.

What is the significance of Pharvaris' focus on oral therapies?

Oral therapies like deucrictibant aim to improve patient convenience and compliance, offering a more manageable and less invasive option compared to injectable treatments.

What are Pharvaris' future plans?

Pharvaris plans to continue its clinical trials, engage with regulatory authorities, and expand research into other bradykinin-mediated diseases while preparing for the commercial launch of deucrictibant.

Who leads Pharvaris?

Pharvaris is led by a team with deep expertise in HAE and rare diseases, including members who were instrumental in the development and approval of icatibant.

Where can I find more information about Pharvaris?

For more information, visit Pharvaris’ website at https://pharvaris.com/.
Stock PHVS logo
Pharvaris N.V. Ordinary Shares

Nasdaq:PHVS

PHVS Rankings

#2529 Ranked by Market Cap
N/A Ranked by Dividends

PHVS Stock Data

1.02B
32.65M
9.49%
87.51%
0.25%
Biotechnology
Healthcare
Link
United States of America
Leiden